SCHEMBL7051779

SCHEMBL7051779

CCOC(=O)C(CCCc1ccccc1)(C[PH](=O)COS(=O)(=O)c1ccc(C)cc1)OCC

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 3/20 0.37
LMNA P02545 1/20 0.36
CNR2 P34972 1/20 0.36
POLB P06746 1/20 0.36
STAT3 P40763 1/20 0.34
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
PLAU P00749 1/20 0.33
HPN P05981 1/20 0.33
THRB P10828 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052400 0.94 POLB (0.37) FKBP1ALMNACNR2POLBSTAT3
SCHEMBL7050906 0.89 ALDH1A1 (0.38) LMNACNR2POLBSTAT3GAA
SCHEMBL7050155 0.88 PTPRC (0.35) LMNAPOLBALDH1A1THRBMEN1
SCHEMBL7054000 0.81 ALDH1A1 (0.36) LMNAALDH1A1CYP2C9CYP2C19THRB
SCHEMBL7048898 0.81 RECQL (0.38) LMNAALDH1A1THRBRAB9A
SCHEMBL7238354 0.81 ALDH1A1 (0.37) LMNAPOLBSTAT3GAAALDH1A1
SCHEMBL7048017 0.77 ENPP3 (0.37) LMNACNR2POLBSTAT3ALDH1A1
SCHEMBL7047044 0.77 ALDH1A1 (0.35) LMNAPKMALDH1A1THRBMEN1
SCHEMBL7049813 0.74 ALDH1A1 (0.40) LMNAGAAALDH1A1THRBMEN1
SCHEMBL9067917 0.73 ALDH1A1 (0.41) FKBP1ALMNACNR2POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 FKBP1A 396/4885LMNA 488/4885CNR2 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.